Table 1 Ongoing clinical trials to explore combined biomarkers of ICI in NSCLC
Identifier | Time Perspective | Patients | Treatment | Tumor-related biomarkers | TME | Host related biomarkers |
|---|---|---|---|---|---|---|
NCT04918836 | Prospective | Metastatic NSCLC | Initiation of ICI | – | lymphocyte immunophenotyping | autoantibodies, RF, LDH, complement (C3 C4), anti-tissue antibodies |
NCT03578185 | Retrospective | NSCLC | treated with ICI | Neoantigen, TMB, PD-1/PD-L1 expression | T-cell receptor and associated immune gene signature | fecal material |
NCT04589013 | Prospective | metastatic or locally advanced unresectable NSCLC | pembrolizumab + first line chemotherapy | PD-L1 | CD8, FoxP3, PD1, CD163, CD15 | – |
NCT04629027 | Retrospective | IIIB-IV non-squamous NSCLC | ICI | – | T cell marker | CTC |
NCT04923802 | Prospective | stage I-IV NSCLC | ICI | NGS-based genomic, transcriptomic, and methylomic profiling | – | blood samples |
NCT04858828 | Prospective | Advanced NSCLC | immunotherapy combined with chemotherapy in the first-line treatment | PD-L1,TMB, MSI, DDR, | TCR | blood samples |
NCT04636047 | Prospective | NSCLC | ICI | – | HLA,TCR | bTMB |
NCT04804137 | Prospective | Metastatic NSCLC | ICI | – | T cell sub populations, B lymphocytes | sputum, blood samples, intestinal microbiota |
NCT04646837 | Prospective | IB-IIIA NSCLC | neoadjuvant treatment | WES, GEP gene expression profiling, ctDNA | TCR |